Opdualag chalks up another failure, this time in the extension of an approved use.

But investors remain unimpressed with the Nectin-4 ADC Corbus bought for just $7.5m.

Phase 1 data give investors a benchmark for mevrometostat's pivotal Mevpro-1 trial.

But the overall survival benefit in prostate cancer is still driven by HRR mutations.

AbbVie follows Gilead in throwing Xilio a lifeline.

The deal isn’t done, but would be Merck’s biggest oncology buy.